James W. Lillard

James W. Lillard, Ph.D., MBA 

Senior Associate Dean

Research, Innovation and Commercialization

Location: Hugh Gloster Building
Phone: 404-752-1863
E-mail: jlillard@msm.edu


University of Kentucky College of Medicine
Degree: Doctor of Philosophy in  Microbiology & Immunology 

Emory University Goizueta Business SchooL
Degree: Master of Business Administration in Healthcare Track


Ohio State University
Degree: Bachelor of Science in Electrical & Computer Science Engineering 

Research Interests

Dr. Lillard is an immuno-biologist who uses both in silico and in vivo methods to develop biologics to treat chronic diseases. Most recently, his laboratory research involves dissecting the molecular mechanisms of chemokine-mediated solid tumors and heme malignancy progression, using clinically annotated DNA/RNA sequence data. His research contributions span multiple disciplines including oncology, vaccine development, biodefense, and neuro-inflammation. Dr. Lillard’s cumulative peer-reviewed funding principally directed over his scientific career exceeds $30 million and he has authored over 300 scientific communications, which have been cited over 6,000 times.


H. Mir, G. Kaur, N. Kapur, S. Bae, J.W. Lillard, Jr., and S. Singh. 2019. Higher CXCL16 exodomain is associated with aggressive ovarian cancer and promotes the disease by CXCR6 activation and MMP modulation. Sci Rep 9:2527-39. PMID: 30792527

S.K. Singh, M.K. Mishra, I.A. Eltoum, S. Bae, J.W. Lillard, Jr., and R. Singh. 2018. CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells. Sci Rep in press PMID: 29358632

M.B. Huang, R.R. Gonzalez, J. Lillard, and V.C. Bond.  2017. Secretion modification region-derived peptide blocks exosome release and mediates cell cycle arrest in breast cancer cells. Oncotarget 8:11302-15. PMID: 28076321

N. Kapur, H. Mir, C. Clark, III, U. Krishnamurti, D. Beech, J.W. Lillard, Jr., and S. Singh. 2016. CCR6 expression in colon cancer is associated with advanced disease and supports epithelial to mesenchymal transition. Br J Cancer 14: 1343-51. PMID: 27149649

H. Mir, N. Kapur, R. Singh, G. Sonpavde, J.W. Lillard and S. Singh. 2016. Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors. Cell Cycle 15:819-26. PMID: 27029529

R. Singh, N. Kapur, H. Mir, N. Singh, J.W. Lillard Jr., and S. Singh. 2016. CXCR6-CXCL16 axis promotes prostate cancer by mediating cytoskeleton rearrangement via Ezrin activation and αvβ3 integrin clustering. Oncotarget 7:7343-53. PMID: 26799186

R. Singh, P. Gupta, G.H. Kloecker, C.R. Stockard, W.E. Grizzle, S. Singh, and J.W. Lillard, Jr. 2014. Expression and clinical significance of CXCR5/CXCL13 in human non-small cell lung carcinoma. Intl J Oncology [Epub ahead of print] PMID: 25271023

Click here to view additional publications.

Honors and Awards

  • American Association for Cancer Research President’s Initiative -2020 by 2020, Principal Investigator
  • Veterans Affairs, National Research Advisory Council Member
  • NCI U54 MSM/TU/UAB Comprehensive Cancer Center, Multi-Principal Investigator
  • National Institutes of Health Center for Scientific Review, Innate Immunity & Inflammation Study Section Member
  • National Institutes of Health Center for Scientific Review, Cancer Diagnostics & Treatments (CDT) SBIR Peer Review Panel Member
  • National Institutes of Health Center for Scientific Review, Provocative Questions Special Emphasis Peer Review Panel Member
  • World Journal of Medical Research, Editor-in-Chief
  • World Journal of Clinical Oncology, Editorial Board
  • Georgia Cancer Coalition, Distinguished Cancer Scholar Award
  • University of Louisville, Smith & Lucile Gibson Endowed Chair in Medicine
  • United States Food & Drug Administration Transmissible Spongiform Encephalopathy Advisory Panel Member
  • Academy of Microbiologist, Microbial Triggers of Chronic Human Illness Colloquium Member 
  • Crohn’s & Colitis Foundation of America Senior Research Scientist Award